The emergence of antibiotic-resistant bacteria coupled with the dwindling supply of new antibacterial therapeutics has created a medical crisis. Traditional industry-driven approaches that target the active sites of essential enzymes have begun to stall, yielding fewer new antibacterial agents than are needed to combat the alarming wave of drug-resistant pathogens that have become commonplace in clinical settings. Novel approaches to therapeutic discovery are essential for generating effective treatments against emerging bacterial threats. This application tests the utility of protein interfaces, rather than enzyme active sites, as targets for antibacterial drug development. This mode of action takes advantage of the essential nature of protein interactions in supporting cellular processes, which are underexplored therapeutic targets. With its many essential protein interactions, the bacterial DNA replication machinery is an ideal system that will be used to test the robustness of protein interfaces as antibacterial therapeutic targets. High-throughput screens will identify compounds that disrupt bacterial DNA replication protein complexes and the mechanisms of action of the compounds will be determined using a combination of structural, biochemical and cellular studies. Antibiotic activities of the compounds will be assessed with a broad spectrum of bacterial species. The proposed approach will simultaneously test the extent to which protein interfaces can be used for antibacterial drug development and the suitability of DNA replication protein complexes as direct targets for such inhibitors. The rewards of this proposed research could pave the way to much needed antibacterial lead compounds and establish protein interfaces as novel targets for antibacterial drug development.

Public Health Relevance

The explosion of antibiotic-resistant bacteria has created a public health threat that challenges our abilities to treat formerly routine infections. Our projec tests protein interfaces that support bacterial DNA replication as a possible target for the development of novel antibiotics.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants Phase II (R33)
Project #
4R33AI111676-03
Application #
9222869
Study Section
Special Emphasis Panel (NSS)
Program Officer
Ernst, Nancy Lewis
Project Start
2016-03-15
Project End
2019-02-28
Budget Start
2016-03-15
Budget End
2017-02-28
Support Year
3
Fiscal Year
2016
Total Cost
$447,340
Indirect Cost
$147,340
Name
University of Wisconsin Madison
Department
Biochemistry
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Voter, Andrew F; Killoran, Michael P; Ananiev, Gene E et al. (2018) A High-Throughput Screening Strategy to Identify Inhibitors of SSB Protein-Protein Interactions in an Academic Screening Facility. SLAS Discov 23:94-101
Voter, Andrew F; Keck, James L (2018) Development of Protein-Protein Interaction Inhibitors for the Treatment of Infectious Diseases. Adv Protein Chem Struct Biol 111:197-222
Bhattacharyya, Basudeb; Keck, James L (2014) Grip it and rip it: structural mechanisms of DNA helicase substrate binding and unwinding. Protein Sci 23:1498-507